Biochemotherapy formetastatic melanoma with limited central nervous system involvement

Oncology

Volumn 64, Issue 4, 2003, Pages 328-335

  Boasberg, Peter D ^a   O'Day, Steven J ^a   Kristedja, Tim S ^a   Martin, Maureen ^a   Wang, Hejing ^a   Deck, Regina ^a   Shinn, Kelly ^a   Ames, Pat ^a   Tamar, Beth ^a   Petrovich, Zbigniew ^b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biochemotherapy; Central nervous system metastases; Gamma Knife radiosurgery; Melanoma

Indexed keywords

CISPLATIN; DACARBAZINE; INTERLEUKIN 2; RECOMBINANT ALPHA2B INTERFERON; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CANCER GROWTH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE COURSE; METASTASIS; MIDDLE AGED; RADIOSURGERY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CISPLATIN; DACARBAZINE; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RADIOSURGERY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0038312286     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070289     Document Type: Article

References (19)

1. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193-201.
2. Balch CM: Cutaneous melanoma: Prognosis and treatment results worldwide. Semin Surg Oncol 1992;8:400-414.
3. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998;88:11-20.
4. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827-835.
5. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-1759.
6. O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17:2752-2761.
7. O'Day SJ, Boasberg PD, Kristedja TS, Martin M, Wang HJ, Fournier P, Cabot M, DeGregorio MW, Gammon G: High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma. Cancer 2001;92:609-619.
8. Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Gonzalez R: A multicenter phase II study of modified biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSF. Proc Am Soc Clin Oncol 2000;19:572a.
9. Ellerhorst J, Strom E, Nardone E, McCutcheon I: Whole brain irradiation for patients with metastatic melanoma: A review of 87 cases. Int J Radiat Oncol Biol Phys 2001;49:93-97.
10. Hillner BE, Kirkwood JM, Agarwala SS: Burden of illness associated with metastatic melanoma: An audit of 100 consecutive referral center cases. Cancer 2001;91:1814-1821.
11. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
12. Chen JC, Petrovich Z, O'Day S, Morton D, Essner R, Giannotta SL, Yu C, Apuzzo ML: Stereotactic radiosurgery in the treatment of metastatic disease to the brain. Neurosurgery 2000;47:268-279.
13. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C: Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci 2000;44:211-218.
14. Chamberlain MC, Kormanik PA: Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999;56:703-708.
15. Biasco G, Pantaleo MA, Casadei S: Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 2001;345:621-622.
16. Margolin K, Atkins AB, Thompson JA, Ernstoff MS, Weber J, Flaherty L, Clark JI, Weiss G, Sosman J, Smith JW II, Dutcher JP, Gollob J, Longmate J, Johnson D: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002;128:214-218.
17. Agarwala SS, Kirkwood JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-151.
18. Yu Y, Zhang JB, Cheng G, Schell MC, Okunieff P: Multi-objective optimization in radiotherapy: Applications to stereotactic radiosurgery and prostate brachytherapy. Artif Intell Med 2000;19:39-51.
19. Saris SC, Patronas NJ, Rosenberg SA, Alexander JT, Frank J, Schwartzentruber DJ, Rubin JT, Barba D, Oldfield EH: The effect of intravenous interleukin-2 on brain water content. J Neurosurg 1989;71:169-174.